@OhioStatePIIO

Pelotonia Institute for Immuno-Oncology. A bench-to-bedside research initiative accelerating therapeutics that use the immune system to fight cancer. #PIIO

 Columbus, OH, USA
cancer.osu.edu/PIIO
Joined October 2021
  • Tweets1.4K
  • Following443
  • Followers1.2K
724Media
Join us for a Distinguished Professor Seminar featuring Giorgio Trinchieri, MD, NIH Distinguished Investigator and Chief of the Laboratory of Integrative Cancer Immunology at the National Cancer Institute. Presentation Title: “Targeting the Microbiome for Cancer Immunotherapy,” 📅 October 28, 2026 🕛 12–1 PM 📍 EAIC 130 For decades, Dr. Trinchieri has been at the forefront of discoveries connecting #inflammation, #innate_immunity, #adaptive_immune_responses, and #cancer. His pioneering research has helped shape our understanding of how the body's #immune_system interacts with tumors and how the #microbiome influences cancer development, progression, and treatment response. This seminar is not to be missed! Presented by the @OSUCCC_James @Pelotonia Institute for Immuno-Oncology (PIIO), Center for Microbiome Research, and Cutaneous & Mucosal Research Center for Immuno-Oncology (CMRCIO).
Promotional seminar graphic from the Pelotonia Institute for Immuno-Oncology. A red-and-black background features enlarged microscopic imagery of bacteria on the left and a cancer cell on the right. Large headline text reads, “Targeting the Microbiome for Cancer Immunotherapy.” Centered below is a photo of the featured speaker. Additional text identifies the speaker as Giorgio Trinchieri, MD, NIH Distinguished Investigator. Event details at the bottom read: Wednesday, October 28, 2026, 12–1 PM, EAIC 130. The Ohio State University Comprehensive Cancer Center logo appears in the footer. The overall design uses bold white and scarlet typography with a scientific and biomedical theme.

ALT Promotional seminar graphic from the Pelotonia Institute for Immuno-Oncology. A red-and-black background features enlarged microscopic imagery of bacteria on the left and a cancer cell on the right. Large headline text reads, “Targeting the Microbiome for Cancer Immunotherapy.” Centered below is a photo of the featured speaker. Additional text identifies the speaker as Giorgio Trinchieri, MD, NIH Distinguished Investigator. Event details at the bottom read: Wednesday, October 28, 2026, 12–1 PM, EAIC 130. The Ohio State University Comprehensive Cancer Center logo appears in the footer. The overall design uses bold white and scarlet typography with a scientific and biomedical theme.

2
4
245
🌵 Let’s connect in Phoenix at #SITC26! Join @OhioStatePIIO for the @OSUCCC_James Scarlet & Gray Reception on November 7! Connect with colleagues, spark new collaborations, and celebrate advances in cancer immunotherapy. 🔗 See you there!: go.osu.edu/DQzw @sitcancer
Invitation from Ohio State’s Pelotonia Institute for Immuno-Oncology to the Scarlet and Gray Reception during SITC 2026. Saturday, November 7, 2026, 6–8 p.m., in the Paradise Valley Room at Sheraton Phoenix Downtown, 340 N. 3rd Street, Phoenix, AZ 85004. The graphic features Ohio State and The James branding above a photo of the hotel at dusk, with the headline “Join Us at SITC 2026.”

ALT Invitation from Ohio State’s Pelotonia Institute for Immuno-Oncology to the Scarlet and Gray Reception during SITC 2026. Saturday, November 7, 2026, 6–8 p.m., in the Paradise Valley Room at Sheraton Phoenix Downtown, 340 N. 3rd Street, Phoenix, AZ 85004. The graphic features Ohio State and The James branding above a photo of the hotel at dusk, with the headline “Join Us at SITC 2026.”

1
10
240
Congratulations to #PIIO member Dr. Margaret Liu & colleagues on their important work toward new strategies for treating #TNBC!
The James at Ohio State@OSUCCC_JamesOct 20
A triple threat for triple-negative breast cancer: New Ohio State research shows that a therapy combo could improve care by killing cancer cells, slowing tumor growth and limiting the cancer’s spread. cancer.osu.edu/news/smart-bo…

'Smart bomb' combination attacks triple-negative breast cancer in preclinical study

A new preclinical study suggests that attacking triple-negative breast cancer in two ways at once can kill cancer cells, slow tumor growth and limit the

cancer.osu.edu
2
265
🎉 Congratulations to Aharon G. Freud, MD, PhD, Casey Cosgrove, MD, and Christopher C. Oakes, PhD on receiving a Soter Summit Award! Their project, Clinical and Genetic Factors Molding #NKCell Functions in #EndometrialCancer, was selected for funding through the Soter Women’s Health Research Program, supporting innovative, collaborative research to advance #WomensHealth. 👏🔬
Graphic announcing a Soter Summit Award for advancing women's health research. The graphic features Ohio State University Comprehensive Cancer Center branding and highlights a $250,000 award over three years. Three researcher headshots are displayed with the names Aharon G. Freud, MD, PhD, Casey Cosgrove, MD, and Christopher C. Oakes, PhD beneath each photo. A project title box at the bottom reads: “Clinical and Genetic Factors Molding NK Cell Functions in Endometrial Cancer.” The design uses scarlet, gray, and white colors with a women's health symbol and clean academic branding.

ALT Graphic announcing a Soter Summit Award for advancing women's health research. The graphic features Ohio State University Comprehensive Cancer Center branding and highlights a $250,000 award over three years. Three researcher headshots are displayed with the names Aharon G. Freud, MD, PhD, Casey Cosgrove, MD, and Christopher C. Oakes, PhD beneath each photo. A project title box at the bottom reads: “Clinical and Genetic Factors Molding NK Cell Functions in Endometrial Cancer.” The design uses scarlet, gray, and white colors with a women's health symbol and clean academic branding.

1
1
13
483
🎉 Big congratulations to #PIIO Member, Robert Baiocchi, MD, PhD, on earning a prestigious @theNCI R01 grant award! This highly competitive funding will support innovative research advancing the understanding of post-transplant #lymphoproliferative_disorders (PTLD) and future treatment strategies. A tremendous achievement for Dr. Baiocchi, his collaborators, and the @OSUCCC_James research community. 👏🔬
Graphic of Dr. Baiocchi pictured in white coat and tie. Text: Congratulations! NCI R01 Grant Award. Research focused on advancing the understanding of post-transplant lymphoproliferative disorders (PTLD) and related translational cancer studies

ALT Graphic of Dr. Baiocchi pictured in white coat and tie. Text: Congratulations! NCI R01 Grant Award. Research focused on advancing the understanding of post-transplant lymphoproliferative disorders (PTLD) and related translational cancer studies

1
1
13
857
We’re looking forward to today's #Immunology, #Infection, & #ImmunoOncology (i3) Seminar Series at NOON, where Dr. Benjamin Vincent of UNC Lineberger Comprehensive Cancer Center will present “Opportunities and Challenges in Personalized Immunotherapy for Cancer.” An Associate Professor of Medicine, Dr. Vincent combines experimental and computational immunology to uncover why cancers respond to—or resist—vaccines and cellular immunotherapies, advancing the science behind more personalized treatment. 📍 Presentation: DHLRI 170 📺 Viewing rooms: PRC 3001 & NCH RB2.5.1 Sponsored by @OhioStatePIIO #CME credits available! @OhioState #MIIProud @OhioStateRheum #CancerImmunotherapy
Flier for Dr. Vincent's seminar. Photo of Dr. Vincent. Information on the flier contained in the post

ALT Flier for Dr. Vincent's seminar. Photo of Dr. Vincent. Information on the flier contained in the post

2
146
🎉 50 years of discovery. 50 years of innovation. 50 years of transforming lives at The @OSUCCC_James! Grateful for the visionary leaders who built this legacy and for Dr. @KimrynRathmell's leadership in shaping the future of cancer research and care. A powerful session, From Discovery to Bedside: Patient Perspectives, was moderated by @Pelotonia CEO Joe Apgar. Survivors shared moving stories that reminded us WHY we do what we do. 👏 A standing ovation—and renewed inspiration to keep discovering, keep innovating, and keep fighting for more survivors, more birthdays, and more life! ❤️ #OSUCCCJames #CancerResearch #Pelotonia
The James at Ohio State@OSUCCC_JamesOct 16
Oncology experts are discussing the past, present and future of cancer research at our Annual Scientific Meeting. This year’s event is a celebration of the depth, innovation and impact of the OSUCCC – James as we mark 50 years of cancer research @OhioState.
2
8
658
Pelotonia Institute for Immuno-Oncology retweeted
The James at Ohio State@OSUCCC_JamesOct 16
Oncology experts are discussing the past, present and future of cancer research at our Annual Scientific Meeting. This year’s event is a celebration of the depth, innovation and impact of the OSUCCC – James as we mark 50 years of cancer research @OhioState.
4
2
5
1,788
Pelotonia Institute for Immuno-Oncology retweeted
The James at Ohio State@OSUCCC_JamesOct 13
On our Cancer-Free World Podcast, Sameek Roychowdhury, MD, PhD, explains why researchers are working in labs across the world to discover new checkpoint therapies that could lead to improved immunotherapy treatment. New episode: go.osu.edu/DQdS
3
4
360
Pelotonia Institute for Immuno-Oncology retweeted
The Ohio State University Wexner Medical Center@OSUWexMedOct 15
A new immunotherapy approach developed by Dr. Margaret Gatti-Mays uses naturally occurring immune cells from healthy donors that are modified to resist cancer cells’ attempts to destroy them. health.osu.edu/health/cancer…

Researcher creates new immunotherapy for breast cancer

Patients @OSUCCC_James are the first to enroll in a clinical trial testing a new immunotherapy combination for metastatic breast cancer.

health.osu.edu
1
2
502
Pelotonia Institute for Immuno-Oncology retweeted
Ohio State Medical Oncology@OhioStateMedOncOct 13
📝New publication from Merve Hasanov in Neuro-Oncology Advances: Clinical factors associated with leptomeningeal disease in patients with melanoma brain metastasis doi.org/10.1093/noajnl/vdag2…

Clinical factors associated with leptomeningeal disease in patients with melanoma brain metastasis

AbstractBackground. Leptomeningeal disease (LMD) is a severe manifestation of metastatic cancer with limited treatment options and a poor prognosis. Melano

academic.oup.com
4
9
527
🎉 Congrats to #PIIO/Department of Molecular Medicine and Therapeutics recruit Dr. Peter Chockley @PeterChockley on his @BloodAdvances publication! A newly identified #NKcell receptor interaction helps predict survival after stem cell transplant. 🔗 doi.org/10.1182/bloodadvance…
Publication celebration graphic congratulating Dr. Peter Chockley, a PIIO and Department of Molecular Medicine and Therapeutics recruit, on his Blood Advances paper identifying a new KIR2DS4:HLA-B*35 interaction that predicts survival after stem cell transplant. Scarlet-and-white design includes The James branding, illustrations of immune cells interacting with leukemia cells, and a gray square reserved for his photo.

ALT Publication celebration graphic congratulating Dr. Peter Chockley, a PIIO and Department of Molecular Medicine and Therapeutics recruit, on his Blood Advances paper identifying a new KIR2DS4:HLA-B*35 interaction that predicts survival after stem cell transplant. Scarlet-and-white design includes The James branding, illustrations of immune cells interacting with leukemia cells, and a gray square reserved for his photo.

1
6
572
🚨 Heading to #SITC26 in Phoenix? 🌵 Join @OhioStatePIIO at the @OSUCCC_James Scarlet & Gray Reception on November 7—an evening of networking, collaboration, and celebrating the innovations shaping the future of cancer immunotherapy! 🔗 Register now: go.osu.edu/DQzw @sitcancer
1
1
203
Congratulations to @OSUCCC_James, @OhioStateMedOnc, #PIIO physician-scientist, Dr. Elshad Hasanov (@HasanovLab) on receiving a @GatewayforCR award to fund ZUMRA study, a multicenter phase II clinical trial for patients with #KidneyCancer and #BrainMetastasis! ZUMRA study will test zanzalintinib alone or in combination with belzutifan in patients with untreated or progressive #BrainMetastases, a population often excluded from major clinical trials. The study will evaluate whether these treatments shrink brain metastases, while also assessing safety, duration of cancer control, and survival. An important step toward expanding treatment options and bringing hope to patients with challenging-to-treat kidney cancer. #KidneyCancer #ClinicalTrials #CancerResearch
7
21
717
Congratulations to @OSUCCC_James, @OhioStateMedOnc, #PIIO researchers Drs. Ephraim Ansa-Addo and @Zihai Li (PIIO Director) on the publication of their groundbreaking research in @NatureComms! 🎉 Their study reveals how the chromatin organizer SATB1 regulates tumor-promoting Treg activity—pointing toward a potential strategy to enhance antitumor immunity without triggering systemic autoimmunity. Years in the making, this impactful science and the novelty of this discovery are a testament to persistence, collaboration, and scientific innovation. Congratulations to Ephraim, Zihai, and the entire team! 🔗 nature.com/articles/s41467-0… #CancerResearch #Immunotherapy #TumorImmunology #Tregs @OhioStateMedOnc
2
5
16
800
The ride may be over, but the mission keeps moving forward. 🚲❤️ Every mile traveled today reflects the strength of a community working together toward a cancer-free world. #GravelDay #Pelotonia #TeamBuckeye
5
259
Finish line feeling! 🎉🚴 Congratulations to our Gravel Day riders on completing an incredible day of miles, memories and meaningful impact! #GravelDay #TeamBuckeye #Pelotonia
2
184
🚴💪 Our Gravel Day riders are taking a well-earned break before heading back out for more miles. Keep it going! #GravelDay #TeamBuckeye #Pelotonia
2
174
Behind every great ride is an incredible team. ❤️🙌 Thank you to our Gravel Day volunteers for keeping riders fueled, encouraged and ready for the miles ahead! #GravelDay #TeamBuckeye #BuckeyesAsOne
3
120
Fuel up, hydrate and share a few smiles! 🍌💧🚲 The energy at the Gravel Day rest stops is going strong. Next stop: more gravel! #GravelDay #Pelotonia #TeamBuckeye
1
5
243
Load more